Iron and Reduced Deferral Rate

Doses used in studies

Safety in these studies

abdominal painIncreased riskRR 1.69, 95% CI 1.15 to 2.47
More participants may experience adverse events with oral iron compared to no iron, including abdominal pain, constipation, and diarrhoea (RR 1.69, 95% CI 1.15 to 2.47; 8 studies, 2641 participants)
from: Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia
constipationIncreased riskRR 1.69, 95% CI 1.15 to 2.47
More participants may experience adverse events with oral iron compared to no iron, including abdominal pain, constipation, and diarrhoea (RR 1.69, 95% CI 1.15 to 2.47; 8 studies, 2641 participants)
from: Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia
diarrhoeaIncreased riskRR 1.69, 95% CI 1.15 to 2.47
More participants may experience adverse events with oral iron compared to no iron, including abdominal pain, constipation, and diarrhoea (RR 1.69, 95% CI 1.15 to 2.47; 8 studies, 2641 participants)
from: Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia
weaknessReported
There may be no difference in reported non-gastrointestinal symptoms, except a feeling of 'weakness', which was reduced with oral iron supplements.
from: Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia

1 of 1 paper

Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors.